HeartLung Receives FDA “Breakthrough” Designation and Marketing Authorization for the First AI to Enable Opportunistic Detection of Hidden Heart Disease in Millions of CT Scans
![Pattern 5 [Converted]-01.png](https://static.wixstatic.com/media/51c62d_44f38c257d614130ace0f56455e9be12~mv2.png/v1/fill/w_980,h_718,al_c,q_90,usm_0.66_1.00_0.01,enc_avif,quality_auto/51c62d_44f38c257d614130ace0f56455e9be12~mv2.png)
Knowledge Center
HeartLung's distinguished advisor, Dr. Claudia Henschke, who pioneered lung cancer screening, wins the RSNA 2024 Scientific Excellence Award 🏆⚕️
HeartLung Technologies to Present Four Scientific Research Studies on AI-CAC™, AutoBMD™, and AI-CVD™ at the 2024 Radiological Society of North America (RSNA 2024)
HeartLung Technologies Presented AI-CAC™ and AI-CVD™ Research Studies at the Annual Scientific Sessions of the American Heart Association 2024
HeartLung Technologies Receives FDA “Breakthrough” Designation and Marketing Authorization for AutoChamber™
Seven Groundbreaking AI-Enabled Research Studies to be Presented at the Annual Congress of the European Society of Cardiology 2024 in London